An exploratory study of dapagliflozin for the attenuation of albuminuria in patients with heart failure and type 2 diabetes mellitus
Latest Information Update: 08 Jun 2022
Price :
$35 *
At a glance
- Drugs Dapagliflozin (Primary) ; Antihyperglycaemics
- Indications Heart failure; Renal failure; Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms DAPPER study
- 10 Dec 2021 Status changed from recruiting to completed.
- 06 Jun 2020 Planned number of patients changed from 446 to 288.
- 05 Jan 2018 Status changed from not yet recruiting to recruiting.